2024 Greatest T1D Hits: A Glance at This Year’s Achievements
With the holiday season in full swing, we have many reasons to be thankful. While we look back on 2024,…
Breakthrough T1D T1D Fund Invests in vTv Therapeutics
With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin…
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now…
Eli Lilly Acquires Breakthrough T1D T1D Fund Portfolio Company Protomer Technologies
Breakthrough T1D is excited to announce that the T1D Fund portfolio company Protomer Technologies, who is developing "smart" insulin, has been acquired by Eli…
Study: Disease-Modifying Therapies Needed to Offset Costs of Type 1 Diabetes
A new study commissioned by the Breakthrough T1D T1D Fund spotlights the high economic burden of type 1 diabetes (T1D)…
